AVITA Medical CFO granted stock and options

AVITA Medical, Inc. CFO David D. O'Toole reported equity compensation awards consisting of stock options and restricted stock units.

Rhea-AI Filing Summary

AVITA Medical, Inc. CFO David D. O'Toole reported equity compensation awards consisting of stock options and restricted stock units. He acquired 155,510 stock options with an exercise right to buy common shares, and 105,470 shares of common stock in the form of restricted stock units, both at a stated price of $0.00 per share.

The RSUs represent rights to receive one share of common stock each, vesting in three equal annual installments starting 12 months after the February 18, 2026 grant date. The stock options also vest in three equal annual installments beginning on the first anniversary of the same grant date, aligning his compensation with longer-term company performance.

Insider Trade Summary

Grant/Award: 260,980 shares

Grant/Award 2 txns

Insider O'Toole David D

Role CFO

Type	Security	Shares	Price	Value
Grant/Award	Stock Options (Right to Buy)	155,510	$0.00	$0.00
Grant/Award	Common Stock	105,470	$0.00	$0.00

Holdings After Transaction: Stock Options (Right to Buy) — 155,510 contracts (Direct); Common Stock — 137,127 shares (Direct)

Footnotes (3)

1. F1. Represents an award of restricted stock units (the "RSUs"), each RSU representing a contingent right to be issued one share of Common Stock of the Company (the "Common Stock"), that are subject to time-based vesting criteria. These RSUs vest in three equal annual installments beginning on the date 12 months following the grant date of February 18, 2026.
2. F2. Includes unvested RSUs.
3. F3. These Stock Options vest in three equal annual installments beginning the first anniversary of the grant date of February 18, 2026.

FAQ

What did AVITA Medical (RCEL) CFO David O'Toole report on this Form 4?

AVITA Medical CFO David O'Toole reported equity awards rather than open-market trades. He received 155,510 stock options and 105,470 restricted stock units as compensation, aligning his potential future ownership with the company’s long-term performance through multi-year vesting schedules.

How many stock options were granted to the AVITA Medical CFO on February 18, 2026?

The CFO received 155,510 stock options on February 18, 2026. These options give him the right to buy AVITA Medical common shares and vest in three equal annual installments starting on the first anniversary of the February 18, 2026 grant date.

What restricted stock unit (RSU) grant did AVITA Medical (RCEL) disclose for its CFO?

The filing shows an award of 105,470 restricted stock units to the CFO. Each RSU represents a contingent right to one share of common stock and vests in three equal annual installments beginning 12 months after the February 18, 2026 grant date.

Are the AVITA Medical CFO’s new RSUs and options immediately vested?

No, the awards are subject to time-based vesting. The RSUs vest in three equal annual installments beginning 12 months after February 18, 2026, while the stock options vest in three equal annual installments starting on the first anniversary of that grant date.

Does the AVITA Medical Form 4 show insider buying or selling in the market?

The Form 4 reflects equity compensation awards, not market trades. The CFO acquired stock options and RSUs at a stated $0.00 per-share price as grants, indicating compensation-related transactions rather than discretionary buying or selling of AVITA Medical common stock.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/19/2026 - 04:38 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

O'Toole David D

(Last) (First) (Middle)

28159 AVENUE STANFORD

SUITE 220 - AVITA MEDICAL

(Street)

VALENCIA CA 91355

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
AVITA Medical, Inc. [ RCEL ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CFO

3. Date of Earliest Transaction (Month/Day/Year)
02/18/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/18/2026	02/18/2026	A		105,470	A	(1)	137,127(2)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Options (Right to Buy)	$4.31	02/18/2026		A		155,510		(3)	02/18/2036	Common Stock	155,510	$0	155,510	D

Explanation of Responses:

1. Represents an award of restricted stock units (the "RSUs"), each RSU representing a contingent right to be issued one share of Common Stock of the Company (the "Common Stock"), that are subject to time-based vesting criteria. These RSUs vest in three equal annual installments beginning on the date 12 months following the grant date of February 18, 2026.

2. Includes unvested RSUs.

3. These Stock Options vest in three equal annual installments beginning the first anniversary of the grant date of February 18, 2026.

	David O'Toole	02/19/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.